Publications by authors named "K R Moseley"
Updated practice guideline for dual-energy X-ray absorptiometry (DXA).
Eur J Nucl Med Mol Imaging
September 2024
Article Synopsis
- The introduction of dual-energy X-ray absorptiometry (DXA) in the 1980s transformed how osteoporosis is diagnosed and managed globally.
- DXA results can be impacted by various technical factors, including instrument quality, patient positioning, and the interpretation of T-scores and Z-scores.
- This report aims to highlight important technical and clinical elements of DXA use and discusses how to better integrate these practices into clinical settings, along with considering non-bone mineral density measurements.
Osteoporotic fractures, also known as fragility fractures, are reflective of compromised bone strength and are associated with significant morbidity and mortality. Such fractures may be clinically silent, and others may present clinically with pain and deformity at the time of the injury. Unfortunately, and even at the time of detection, most individuals sustaining fragility fractures are not identified as having underlying metabolic bone disease and are not evaluated or treated to reduce the incidence of future fractures.
View Article and Find Full Text PDFUnlabelled: Osteoporosis treatment following arthroplasty for femoral neck fracture (FNF) is associated with lower rates of periprosthetic fracture (PPF). Our study evaluated the economic viability of treatment in patients following arthroplasty and demonstrates that treatment with oral bisphosphonates can be cost-effective in preventing PPF.
Introduction: Osteoporosis treatment following arthroplasty for femoral neck fracture (FNF) is associated with lower rates of periprosthetic fracture (PPF).
Background: T cells in people with human immunodeficiency virus (HIV) demonstrate an exhausted phenotype, and HIV-specific CD4 T cells expressing programmed cell death 1 (PD-1) are enriched for latent HIV, making antibody to PD-1 a potential strategy to target the latent reservoir.
Methods: This was a phase 1/2, randomized (4:1), double-blind, placebo-controlled study in adults with suppressed HIV on antiretroviral therapy with CD4 counts ≥350 cells/μL who received 2 infusions of cemiplimab versus placebo. The primary outcome was safety, defined as any grade 3 or higher adverse event (AE) or any immune-related AE (irAE).